

# 1 **Effect of COVID-19 on Lipid Profile and its Correlation** 2 **with Acute Phase Reactants**

3 **Running head: Hypolipidemia in COVID-19**

4 **Dr. Jahanzeb Malik<sup>1\*</sup>, Dr. Talha Laique<sup>2</sup>, Dr. Uzma Ishaq<sup>3</sup>, Dr. Amna Ashraf<sup>4</sup>, Dr. Asmara**  
5 **Malik<sup>5</sup>, Dr. Mommana Ali<sup>5</sup>, Dr. Syed Muhammad Jawad Zaidi<sup>6</sup>, Dr. Muhammad Javaid<sup>1</sup>,**  
6 **Dr. Asad Mehmood<sup>1 & 7</sup>**

7 **1 Department of Cardiology, Rawalpindi Institute of Cardiology, Rawal Road, 46000,**  
8 **Rawalpindi, Pakistan**

9 **2 Department of Pharmacology, Allama Iqbal Medical College, 54000, Lahore, Pakistan**

10 **3 Department of Hematology, Foundation University Medical College, 44000, Islamabad,**  
11 **Pakistan**

12 **4 Department of Medicine, Military Hospital, Saddar, 46000, Rawalpindi, Pakistan**

13 **5 Department of Community Medicine, National University of Medical Sciences, Saddar,**  
14 **46000, Rawalpindi, Pakistan**

15 **6 Department of Medicine, Rawalpindi Medical University, 46000, Rawalpindi, Paksitan**

16 **7 Department of Cardiology, Advanced Diagnostics and Liver Center, 46000, Rawalpindi,**  
17 **Pakistan**

18 **\*Corresponding author: Dr. Jahanzeb Malik, Senior Registrar Cardiology, Rawalpindi**  
19 **Institute of Cardiology, Rawal Road, 46000, Rawalpindi, Paksitan**

20 **[Heartdoc86@gmail.com](mailto:Heartdoc86@gmail.com) Contact # 00923215668347**

21 **Funding: Authors received no specific funding for this investigation**

22 **Conflict of interest: Authors declare no conflicts of interest**

23

## 24 **Abstract**

### 25 **Background and Objective**

26 Coronavirus disease 2019 (COVID-19) manifests as multiple clinical and pathological organ  
27 dysfunctions. It also disrupts metabolic profile due to the release of pro-inflammatory cytokines  
28 causing a systemic inflammation reaction. However, the development and correlation of  
29 dyslipidemia with acute phase reactants is unknown. This investigation was performed to assess  
30 the pathological alterations of low-density lipoprotein cholesterol (LDL-C), high-density  
31 lipoprotein (HDL), triglycerides, and total cholesterol levels in COVID-19 patients.

### 32 **Methods**

33 This was a prospective study performed on real-world patients to assess serum levels of LDL-C,  
34 HDL, TG, TC on COVID-19 patients (mild: 319; moderate: 391; critical: 357) hospitalized at  
35 our center between April 2020 through January 2021. Age- and gender-matched controls who  
36 had their lipid profiles in the same period were included as the control group.

### 37 **Results**

38 LDL-C, HDL, TG, and TC levels were significantly lower in COVID-19 patients when  
39 compared with the control group ( $P < 0.001$ , 0.047, 0.045,  $< 0.001$ , respectively). All parameters  
40 decreased gradually with COVID-19 disease severity (LDL-C: median (IQR), mild: 98 (91,134);  
41 moderate: 97 (81,113); critical: 68 (68,83); HDL: mild: 45 (37,50); moderate: 46 (41,50);  
42 critical: 40 (37,46); TG: mild: 186 (150,245); moderate: 156 (109,198); critical: 111 (98,154);  
43 TC: mild: 224 (212,238); moderate: 212 (203,213); critical: 154 (125,187)). LDL-C, TC, and TG  
44 were inversely correlated with acute phase reactants (interleukin-6 (IL-6), Procalcitonin, C-

45 reactive protein (CRP), and D-dimers). Logistic regression demonstrated lipid profile, thyroid  
46 profile, and acute phase reactants as predictors of severity of COVID-19 disease.

## 47 **Conclusion**

48 Hypolipidemia develops in increasing frequency with severe COVID-19 disease. It inversely  
49 correlates with levels of acute-phase reactants, indicating SARS-COV-2 as the causative agent  
50 for alteration in lipid and thyroid levels.

51 **Keywords:** COVID-19, Hypolipidemia, LDL-C, HDL, total cholesterol

## 52 **Introduction**

53 Coronaviruses include a large family of viruses notorious for causing a multitude of diseases in  
54 humans, ranging from common flu to more serious conditions like Middle Eastern Respiratory  
55 Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS) [1]. The causative agent for  
56 coronavirus disease 2019 (COVID-19) is the SARS coronavirus 2 (SARS-COV-2) that causes  
57 various manifestations of the disease, involving the respiratory, gastrointestinal, hematological,  
58 endocrine, and cardiovascular systems [2,3]. Even after the mitigation measure, the estimated  
59 basic reproduction ( $R_0$ ) ranges from 2.24 to 3.58 and the mortality rate of COVID-19 is  
60 considered to be 2.3% [4,5,6]. World Health Organization (WHO) declared COVID-19 as a  
61 pandemic and initiated a global emergency from 11th March 2020 [7].

62 SARS-COV-2 is a positive-stranded RNA virus with an envelope of lipid bilayer, and a genome  
63 of approximately 30,000 nucleotides. On an electron microscope four major proteins have been  
64 identified as an integral part of the virus: the nucleocapsids (N) protein, the crown or spike (S)  
65 protein, the membrane (M) protein, and the envelope (E) protein [8]. These proteins play an  
66 important role in human infectivity and among them, the S protein mediates attachment to

67 human hosts via angiotensin-converting enzyme 2 (ACE2) receptors [9]. An expression of ACE  
68 2, in combination with transmembrane protease serine 2 (TMPRESS2), seems to be the key  
69 cellular mechanism for human infection [10].

70 In SARS-COV-2, lipids are an essential component for maintaining the integrity of the viral  
71 membrane and its fusion to the host cells, viral replication, endo/exocytosis, and human host  
72 infiltration. Some preliminary reports have described lipid abnormalities associated with the  
73 severity of disease in COVID-19 [11,12]. Therefore, this investigation was aimed to assess the  
74 lipid profile and its correlation with other biochemical tests used to predict the severity of  
75 COVID-19.

## 76 **Methods**

### 77 **Study design and patient demographics**

78 This prospective study was carried out at Infectious Disease Block, Advanced Diagnostics and  
79 Liver Center, Rawalpindi, and was approved by the Review Committee (Study ID#ADC/20/006)  
80 of Advanced Diagnostics and Liver Center according to the ethical principles of the Declaration  
81 of Helsinki. Written, informed consent was taken from all the participants/guardians before data  
82 collection. A total of 1,755 patients were enrolled in this investigation: 1067 with COVID-19 and  
83 688 healthy adults as controls from April 2020 through January 2021. All the data regarding  
84 demographics, epidemiology, comorbidities, laboratory tests, and hospital stay were extracted  
85 electronically. SARS-COV-2 positive patients were confirmed using real-time reverse  
86 transcription-polymerase chain reaction (RT-PCR). Pneumonia was classified according to the  
87 guidelines issued by the Centers for Disease Control (CDC) as labeled as mild, moderate, or  
88 severe on high resolution computed tomography (HRCT) scans according to our previous study

89 [13]. HRCT was considered positive if it demonstrated consolidation, septal thickening, linear  
90 opacities, crazy-paving pattern, or halo sign. Mild disease was classified as less than 10% lung  
91 involvement with normal room oxygen saturation. Moderate cases were classified as less than  
92 50% lung involvement on HRCT with respiratory rate of >30 breaths/min, and oxygen saturation  
93 of < 90% at rest requiring <10 ml/min of oxygen. Those requiring >10 ml/min of oxygen and/or  
94 ventilatory support were labeled as critical cases. Age- and gender-matched healthy adults, who  
95 had their lipid profile panel done at our clinic were included as controls. Their data were not  
96 identified and only age, gender, BMI, and lipid profile were extracted.

### 97 **Laboratory tests**

98 All the laboratory tests were carried out at our certified laboratory in Advance Diagnostics under  
99 the standard procedures of the Punjab Healthcare Commission. Hemoglobin (Hgb), and white  
100 blood cells (WBC) were performed on a Sysmex automated hematology analyzer (XN-3100™).  
101 Alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein  
102 cholesterol (LDL-C), high-density lipoprotein (HDL), total cholesterol (TC), and triglycerides  
103 (TG) were tested on Cobas® c3011 analyzer (Roche Diagnostics). Free triiodothyronine (T3),  
104 free thyroxine (T4), thyroid-stimulating hormone (TSH), interleukin-6 (IL-6), and Procalcitonin  
105 were analyzed via electrochemiluminescent immunoassay (ECLIA) in the Elecsys® 2010  
106 immunoassay system. All parameters were compared between the COVID-19 classification. In  
107 addition, the lipid profile was compared between the control group and COVID-19. All tests  
108 were drawn in a fasting state from the blood samples on admission.

### 109 **Statistical analysis**

110 Data were analyzed with Statistical Package for the Social Sciences (SPSS) version 26 (IBM  
111 Corp, Armonk, NY, USA.). Normally distributed continuous variables were presented as mean  $\pm$

112 standard deviation (SD) while Non-normally distributed variables as median (interquartile  
113 range). Categorical variables were presented in frequency and percentages. Normality test  
114 adjustment was applied through the Shapiro-Wilk test. The groups were compared using  
115 Student's t-test (normal distribution) and the Mann-Whitney U test (non-normal distribution).  
116 Chi-square was used to compare categorical variables and the Kruskal-Wallis test was used to  
117 compare variables among multiple groups. A receiver operating characteristic (ROC) curve was  
118 calculated for all laboratory parameters to demonstrate sensitivity and specificity in the COVID-  
119 19 cohort. Odds ratio (OR) and confidence interval (CI) were presented for all tests performed.  
120 Scatter plots were demonstrated using Pearson correlation analysis. A p-value of less than 0.05  
121 was considered significant.

## 122 **Results**

123 A total of 1067 COVID-19 patients were included in this investigation: 319 were mild, 391  
124 moderate, and 357 as critical cases. The ages for the COVID-19 cohort was approximately  
125 similar: mild ( $47.83 \pm 19.66$  years), moderate ( $47.87 \pm 19.21$  years), and critical ( $47.29 \pm 18.76$   
126 years) while the mean age for age- and gender-matched control subjects was  $57.37 \pm 4.62$  years.  
127 The patients in this group were significantly older than the COVID-19 cohort. Both COVID-19  
128 and control groups had a majority of the male population (66.7% and 68.4%,  
129 respectively). **Table 1** demonstrates patient demographics and lab parameters in the control as  
130 well as COVID-19 groups. Forty-seven patients did not survive with a mortality rate of 4.4%.  
131 Biochemistry and hematology results showed that Hgb was significantly more in mild cases  
132 while WBC was increased in moderate and critical cases. AST, ALT, creatinine, CRP, D-dimers  
133 were all significantly increased in higher COVID-19 class while free T3, free T4, and TSH were  
134 markedly reduced in critical cases (**Table 1**). LDL-C, HDL, TC, and TG levels were

135 significantly lower in COVID-19 patients as compared to control subjects. All lipid profiles  
136 decreased gradually and significantly in critical cases as compared with mild and moderate  
137 cases. **Figure 1** and **Table 2** demonstrate the receiver operating characteristic (ROC) curve  
138 exhibiting the sensitivity and specificity of the lab parameters in predicting the progression of  
139 COVID-19 disease. Correlation of LDL-C, HDL, TC, and TG with acute phase reactants is  
140 shown in **Figure 2**.

141 Logistic regression analysis was performed to determine predictors of severe COVID-19 disease  
142 among all subjects. The model suggested LDL-C, HDL, TC, TG, free T3, free T4, TSH, IL-6,  
143 Procalcitonin, CRP, and D-dimers as independent risk factors for COVID-19 (**Table 3**).

## 144 **Discussion**

145 Key findings of this investigation were as follows: Levels of LDL-C, HDL, TC, and TG all  
146 decreased significantly with increasing severity of COVID-19 while acute phase reactants like  
147 IL-6, Procalcitonin, CRP, and D-dimers were increased in this cohort and thyroid function tests,  
148 lipid profile parameters, and acute phase reactants were predictors of severe disease of COVID-  
149 19. This is the first prospective report with lipid profile data of real-world patients suffering from  
150 COVID-19 and this investigation points out that lipid levels start decreasing even in mild cases  
151 while reduced lipid levels inversely correlate with acute phase reactants. Also, it provides  
152 evidence of altered biochemistry and pathological evolution of lipidology in COVID-19.

153 Viral infections cause alterations of lipid biomarkers in their hosts, leading to disrupted  
154 cholesterol rafts. This helps them in infiltrating the host defenses. In response to acute  
155 inflammatory conditions in COVID-19, termed as cytokine storm, there is dysfunction of HDL  
156 and LDL-C particles. In addition, a surge of pro-inflammatory cytokines can cause a  
157 consumption of albumin, ApoA1, HDL, TC, TG, LDL-C, along with decreased lymphocytes

158 [14]. Therefore, according to our study, the depressed lipid parameters can be a predictor for the  
159 severity of COVID-19 disease [11]. Similarly, a study in China described the lipid profile and  
160 other clinical characteristics of COVID-19 [15]. The levels of LDL-C, HDL, and TC were  
161 significantly decreased in their patients, and this alteration was gender-specific. In contrast to our  
162 study, males more commonly presented with lowered lipid levels in their investigation. A  
163 significant decrease in HDL was seen only in critical cases of COVID-19 while a significant  
164 decrease of LDL-C, TC, and TG was observed in all COVID-19 groups (mild, severe, critical).  
165 However, in our study HDL, LDL-C, TG, and TC were significantly depressed only in the  
166 critical COVID-19 cohort. In contrast to these investigations, a preprint reports significantly  
167 increased levels of LDL-C compared to control groups and a positive relationship of COVID-19  
168 severity with elevated lipid profile alterations [16].

169 Similar findings have been demonstrated in human immunodeficiency virus (HIV), where  
170 acquired immunodeficiency syndrome (AIDS) patients exhibit an elevated level of plasma  
171 triglycerides and decreased HDL and LDL-C [17]. Furthermore, HIV-infected individuals have  
172 the propensity to develop various other lipid abnormalities like hypocholesterolemia and  
173 decreased free fatty acids [18]. A study analyzed lipid metabolism in SARS-recovered patients at  
174 12 years' interval and demonstrated hypertriglyceridemia and an elevated very-low-density  
175 lipoprotein (VLDL) cholesterol [19].

176 These findings can be explained by the composition of HDL, which contains esterified  
177 cholesterol, Apo-lipoproteins, and triglycerides. These lipid fragments impart an important role  
178 in small-vessel vasodilation, and in the reduction of oxidation and free radical formation,  
179 apoptosis, thrombosis, infection, and inflammation [20]. In addition to its contribution as an anti-  
180 inflammatory lipoprotein, HDL downregulates inflammatory mediators by inactivating T-cells



181 and macrophages [21]. In COVID-19, a surge in pro-inflammatory cytokines confer the presence  
182 of systemic inflammation. HDL can deactivate this inflammatory cascade by inhibiting the  
183 activation of monocytes and neutrophils while maintaining an antioxidant function, allowing for  
184 the removal of oxidized lipids and neutralizing oxidative factors. This in turn mitigates  
185 inflammatory response in the host cells [22]. During a cytokine storm in COVID-19, HDL and  
186 LDL-C are oxidized, leading to an upregulation of immune activation [23,24]. Based on the  
187 immunomodulatory mechanism of HDL, we can consider immune regulation in COVID-19 as  
188 the primary cause for decreased lipid levels in this investigation.

189 There were several limitations of this investigation. First, the time of symptom onset to the time  
190 of sample collection was variable in this cohort. Therefore, the analysis might represent  
191 heterogeneous results of the COVID-19 disease course. Second, many patients were already on  
192 statin treatment and the level of precise alteration in lipid profile during the disease course of the  
193 COVID-19 cohort could be biased towards depressed lipid levels in these patients. Third, the  
194 control group patients were healthy individuals with no severe or critical form of acute illness.  
195 This could have produced a sample selection bias, producing abnormal results in this  
196 investigation. Fourth, no follow-up data of the lipid profile and its alteration was collected for  
197 monitoring the dynamics of COVID-19. This will be needed for better characterization of this  
198 phenomenon in the COVID-19 cohort.

## 199 **Conclusion**

200 The ongoing COVID-19 outbreak caused by SARS-COV-2 poses a great challenge to the human  
201 population with a pressing need to understand viral mechanisms and develop effective antiviral  
202 agents. As cholesterol is involved in many vital cellular processes in regulating the viral entry  
203 into the host cell, the results of this investigation demonstrate a correlation of the severity of

204 COVID-19 disease with altered lipid profile parameters. Decreased levels of LDL-C, HDL, TC,  
205 and TG validate the mechanism of immune upregulation by HDL and its byproducts, causing a  
206 negative correlation between lipids and acute phase reactants released as pro-inflammatory  
207 cytokines in COVID-19.

208 **Acknowledgement:** None

209 **Ethics statement/Informed consent statement:** Advanced Diagnostics and Liver Center gave  
210 express permission after approval from the review board of Advanced Diagnostics and Liver  
211 Center to collect data within its facilities (ID# ADC/20/006) for this investigation. All  
212 participants gave written/informed consent before data collection. **Ethics Committee:** Ethical  
213 review board of Advanced Diagnostics and Liver Center, Rawalpindi, Pakistan.

214 **Author contribution:** JM: concept, methodology, formal analysis, critical review and final  
215 draft; TL: first draft and critical review and final draft; UI: supervision, data curation, first draft;  
216 AA: methodology, first draft; AM: first draft, formal analysis; MAR: first draft, critical review  
217 and final draft; SMJZ: first draft, methodology, data curation; MJ: data curation, methodology;  
218 AM: data curation, methodology, critical review and final draft

219 **Word count: 2172**

## 220 **References**

- 221 1. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Middle East  
222 respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study  
223 Group. *J Virol.* 2013 Jul;87(14):7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15.  
224 PMID: 23678167; PMCID: PMC3700179.

- 225 2. Malik J, Javaid M, Majedi O, Ishaq U, Zahid T. Paying in Blood: A Case of  
226 Thrombocytopenia in Covid-19. *Cureus*. 2020 Aug 16;12(8):e9791. doi:  
227 10.7759/cureus.9791. PMID: 32953307; PMCID: PMC7491688.
- 228 3. Kunutsor SK, Laukkanen JA. Cardiovascular complications in COVID-19: A systematic  
229 review and meta-analysis. *J Infect*. 2020 Aug;81(2):e139-e141. doi:  
230 10.1016/j.jinf.2020.05.068. Epub 2020 Jun 3. PMID: 32504747; PMCID: PMC7832225.
- 231 4. Javed N, Khawaja H, Malik J, Ahmed Z. Endocrine dysfunction in psychology during social  
232 distancing measures. *Bratisl Lek Listy*. 2020;121(12):878-880. doi: 10.4149/BLL\_2020\_144.  
233 PMID: 33300357.
- 234 5. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, Lou Y, Gao D, Yang L, He D, Wang MH.  
235 Preliminary estimation of the basic reproduction number of novel coronavirus (2019-  
236 nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the  
237 outbreak. *Int J Infect Dis*. 2020 Mar;92:214-217. doi: 10.1016/j.ijid.2020.01.050. Epub 2020  
238 Jan 30. PMID: 32007643; PMCID: PMC7110798.
- 239 6. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel  
240 coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol*. 2020 Apr;92(4):441-447. doi:  
241 10.1002/jmv.25689. Epub 2020 Feb 12. PMID: 31994742; PMCID: PMC7167192.
- 242 7. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread,  
243 severity, and inaction. *BMJ*. 2020 Mar 12;368:m1036. doi: 10.1136/bmj.m1036. PMID:  
244 32165426.
- 245 8. Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical characterization of SARS-  
246 CoV-2 nucleocapsid protein. *Biochem Biophys Res Commun*. 2020 Jun 30;527(3):618-623.

- 247 doi: 10.1016/j.bbrc.2020.04.136. Epub 2020 Apr 30. PMID: 32416961; PMCID:  
248 PMC7190499.
- 249 9. Momtazi-Borojeni AA, Banach M, Reiner Ž, Pirro M, Bianconi V, Al-Rasadi K, Sahebkar A.  
250 Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient  
251 Therapeutic Targets to Treat COVID-19. *Angiology*. 2021 Feb;72(2):122-130. doi:  
252 10.1177/0003319720952284. Epub 2020 Aug 30. PMID: 32864982.
- 253 10. Strobe JD, PharmD CHC, Figg WD. TMPRSS2: Potential Biomarker for COVID-19  
254 Outcomes. *J Clin Pharmacol*. 2020 Jul;60(7):801-807. doi: 10.1002/jcph.1641. Epub 2020  
255 May 21. PMID: 32437018; PMCID: PMC7280622.
- 256 11. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, Tan W, Wang H. Hypolipidemia is associated  
257 with the severity of COVID-19. *J Clin Lipidol*. 2020 May-Jun;14(3):297-304. doi:  
258 10.1016/j.jacl.2020.04.008. Epub 2020 Apr 30. PMID: 32430154; PMCID: PMC7192140.
- 259 12. Choi GJ, Kim HM, Kang H. The Potential Role of Dyslipidemia in COVID-19 Severity: an  
260 Umbrella Review of Systematic Reviews. *J Lipid Atheroscler*. 2020 Sep;9(3):435-448. doi:  
261 10.12997/jla.2020.9.3.435. Epub 2020 Sep 21. PMID: 33024735; PMCID: PMC7521969.
- 262 13. Malik J, Malik A, Javaid M, Zahid T, Ishaq U, Shoaib M. Thyroid function analysis in  
263 COVID-19: A retrospective study from a single center. *PLoS One*. 2021 Mar  
264 30;16(3):e0249421. doi: 10.1371/journal.pone.0249421. PMID: 33784355.
- 265 14. Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins, and COVID-19: Basic concepts and  
266 clinical applications. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2021 Feb;1866(2):158849.  
267 doi: 10.1016/j.bbalip.2020.158849. Epub 2020 Nov 4. PMID: 33157278; PMCID:  
268 PMC7610134.

- 269 15. Hu X, Chen D, Wu L, He G, Ye W. Declined serum high density lipoprotein cholesterol is  
270 associated with the severity of COVID-19 infection. *Clin Chim Acta*. 2020 Nov;510:105-  
271 110. doi: 10.1016/j.cca.2020.07.015. Epub 2020 Jul 10. PMID: 32653486; PMCID:  
272 PMC7350883.
- 273 16. Wei C, Wan L, Zhang Y, Fan C, Yan Q, Yang X, et al. Cholesterol Metabolism—Impact for  
274 SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies, *MedRxiv*, 2020,  
275 <https://doi.org/10.1101/2020.04.16.20068528>.
- 276 17. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids,  
277 lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus  
278 infection and the acquired immunodeficiency syndrome. *J Clin Endocrinol Metab*. 1992  
279 May;74(5):1045-52. doi: 10.1210/jcem.74.5.1373735. PMID: 1373735.
- 280 18. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia  
281 is associated with immune dysfunction in early human immunodeficiency virus-1  
282 infection. *Am J Med*. 1993 May;94(5):515-519. doi: 10.1016/0002-9343(93)90087-6. PMID:  
283 7605397.
- 284 19. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered Lipid Metabolism in Recovered  
285 SARS Patients Twelve Years after Infection. *Sci Rep*. 2017 Aug 22;7(1):9110. doi:  
286 10.1038/s41598-017-09536-z. PMID: 28831119; PMCID: PMC5567209.
- 287 20. Taborda NA, Blanquiceth Y, Urcuqui-Inchima S, Latz E, Hernandez JC. High-Density  
288 Lipoproteins Decrease Proinflammatory Activity and Modulate the Innate Immune  
289 Response. *J Interferon Cytokine Res*. 2019 Dec;39(12):760-770. doi: 10.1089/jir.2019.0029.  
290 Epub 2019 Jul 23. PMID: 31335262.

- 291 21. Thacker SG, Zarzour A, Chen Y, Alcicek MS, Freeman LA, Sviridov DO, et al. High-density  
292 lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome  
293 activation. *Immunology*. 2016 Nov;149(3):306-319. doi: 10.1111/imm.12638. Epub 2016  
294 Aug 28. PMID: 27329564; PMCID: PMC5046053.
- 295 22. Kaji H. High-density lipoproteins and the immune system. *J Lipids*. 2013;2013:684903.  
296 doi: 10.1155/2013/684903. Epub 2013 Jan 30. PMID: 23431458; PMCID: PMC3572698.
- 297 23. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST, Fogelman  
298 AM, Navab M, Yang OO. A biochemical fluorometric method for assessing the oxidative  
299 properties of HDL. *J Lipid Res*. 2011 Dec;52(12):2341-51. doi: 10.1194/jlr.D018937. Epub  
300 2011 Sep 27. PMID: 21957198; PMCID: PMC3220300.
- 301 24. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of  
302 reconstituted high density lipoproteins influences their ability to inhibit endothelial cell  
303 adhesion molecule expression. *J Lipid Res*. 2000 Aug;41(8):1261-7. PMID: 10946014.


304

305

306 **Figure 1. ROC curve analysis of lab parameters showing sensitivity and specificity in**  
307 **predicting severity of COVID-19. Receiver operating characteristic (ROC)**

308 **Figure 2. Correlation of lipid profile with acute phase reactants (interleukin-6,**  
309 **Procalcitonin, C-reactive protein, D-dimers)**


310 **Supporting Documents 1. All data is available in supporting document S1.**



- Source of the Curve**
- LDL mg/dl
  - TG mg/dl
  - TC mg/dl
  - HDL mg/dl
  - procalc ng/ml
  - IL pg/ml
  - Reference Line


Diagonal segments are produced by ties.

medRxiv preprint doi: <https://doi.org/10.1101/2021.04.13.21258142>; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



- Source of the Curve**
- t3 pg/ml
  - t4 ng/dl
  - tsh miu/ml
  - IL pg/ml
  - procalc ng/ml
  - Reference Line

















Diagonal segments are produced by ties.



- Source of the Curve**
- hb g/dl
  - wbc mm3
  - alt unit/l
  - ast unit/l
  - cr mg/dl
  - crp mg/dl
  - ddimer mcg/ml
  - Reference Line

Diagonal segments are produced by ties.





medRxiv preprint doi: <https://doi.org/10.1101/2021.04.13.21255142>; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.